Plain-English translation of NCT07589205 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new medication called IBI3028 for people with advanced solid tumors—cancers that cannot be surgically removed or have spread to other parts of the body. The trial includes several cancer types, such as colorectal cancer, lung cancer, pancreatic cancer, and head and neck cancer. Researchers want to learn whether this medication is safe and effective, and to find the right dose.
Many people with advanced solid tumors have limited treatment options, especially if standard therapies no longer work or are not suitable. This trial is exploring whether this medication could offer a new way to slow or stop cancer growth in these patients.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth or infusion as instructed by the research team, likely visiting the clinic regularly for check-ups, blood tests, and imaging scans to monitor how you are responding. You will continue this treatment for up to 24 months, or until the cancer progresses, you experience unacceptable side effects, or other reasons make it necessary to stop. The trial involves multiple visits across several specialized cancer centers.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Enrollment target
~493 participants
Started
March 2026
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shijie Liu
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.